A novel series of human dihydroorotate dehydrogenase inhibitors discovered by in vitro screening: inhibition activity and crystallographic binding mode.Zeng, T., Zuo, Z., Luo, Y., Zhao, Y., Yu, Y., Chen, Q.
(2019) FEBS Open Bio 9: 1348-1354
- PubMed: 31087527
- DOI: https://doi.org/10.1002/2211-5463.12658
- Primary Citation of Related Structures:
- PubMed Abstract:
Human dihydroorotate dehydrogenase (DHODH), the enzyme that catalyzes the rate-limiting step in de novo pyrimidine biosynthesis, is considered to be an attractive target for potential treatment of autoimmune disease and cancer. Here, we present a novel class of human DHODH inhibitors with high inhibitory potency. The high-resolution crystal structures of human DHODH complexed with various agents reveal the details of their interactions. Comparisons with the binding modes of teriflunomide and brequinar provide insights that may facilitate the development of new inhibitors targeting human DHODH.
Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.